<DOC>
	<DOC>NCT01095835</DOC>
	<brief_summary>This study will compare the efficacy and safety of 2 different durations of treatment with pegylated interferon (PEG-IFN) alfa-2a in participants with Hepatitis B e Antigen (HBeAg)-negative chronic hepatitis B virus (HBV). It will also compare PEG-IFN alfa 2a treatment alone and in combination with lamivudine (LAM). The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>adults 1870 years of age; HBeAgnegative chronic hepatitis B for &gt;/=6 months; liver disease consistent with chronic hepatitis B. interferonbased, systemic antiHBV, antiviral, antineoplastic, or immunomodulatory therapy &lt;/=12 months before first dose of study drug; nonresponders to previous interferon therapy; coinfection with hepatitis A, C or D, or with human immunodeficiency virus (HIV); hepatocellular cancer; compensated (Child A, score 6) or decompensated liver disease (Child B or C).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>